A prospective randomised trial to assess the beneficial effect of preoperative hyperoxia therapy on postoperative neuropsychological outcome and inflammatory response after cardiopulmonary bypass

Submission date 12/09/2003	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 12/09/2003	Overall study status Completed	 [_] Statistical analysis plan [X] Results
Last Edited 27/10/2010	Condition category Circulatory System	Individual participant data

Plain English summary of protocol Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Mr Joseph Alex

Contact details

Cardiothoracic Surgery Castle Hill Hospital Cottingham, East Yorkshire United Kingdom HU16 5JQ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N0084118514

Study information

Scientific Title

Study objectives

Does preoperative hyperoxia therapy reduce the serum levels of S100b protein, InterLeukin-6 (IL6), InterLeukin-8 (IL8), L-selectin, P-selectin, Inter-Cellular Adhesion Molecule 1 (ICAM-1), and improve neurological outcome in patients undergoing cardiopulmonary bypass?

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cardiovascular: Cardiopulmonary bypass

Interventions

Randomised controlled trial comparing: 1. Hyperoxia therapy 2. No therapy

Study patients will receive the same intra-operative, postoperative and follow-up care as routine patients and as per unit protocol. A 30-day postoperative neuropsychological assessment will be undertaken. The patient will continue to receive routine postoperative follow-up care as per unit protocol.

The patients will undergo three sessions of hyperoxia therapy in the hyperbaric chamber situated at the BUPA Hospital, Anlaby Road, Hull. Each therapy consists of three 20-minute sessions in the hyperbaric chamber breathing 1005 O2 at 2.5 atmospheres interspread with five minutes of air breathing.

Blood samples will be taken for estimation of serum IL6, IL8, sE-selection, ICAM-1 and neutrophil CD18. This will be taken immediate pre-operation, at the end of the operation, 12 hours, 24 hours, 48 hours and fifth day post-operation. Blood samples for estimation of S100B will be taken immediate pre-operation, at the end of the operation, two hours and four hours after the operation.

A baseline neuropsychological test will be done within 24 h prior to the operation. The first postoperative assessment will be carried out when the performance is more stable, that is, three months postoperatively. To ensure objectivity and reliability of the assessment, the testing of each patient will be undertaken by the same doctor.

Intervention Type

Other

Phase Not Specified

Primary outcome measure

Data collected will be entered into the research department computer and statistical analysis will be done using the Stars Direct Package. Demographics, measures and results of data analysis will be represented as tables, graphs, bar charts and pie charts where applicable. Statistical significance will be set at P-value < 0.05.

Secondary outcome measures

Not provided at time of registration

Overall study start date 07/10/2002

Completion date 15/01/2004

Eligibility

Key inclusion criteria

A total of 50 patients (25 each group), between 20 and 75 years of age undergoing cardiopulmonary bypass.

Participant type(s) Patient

Age group

Adult

Sex

Not Specified

Target number of participants 50

Key exclusion criteria Not provided at time of registration

Date of first enrolment 07/10/2002

Date of final enrolment 15/01/2004

Locations

Countries of recruitment England

United Kingdom

Study participating centre Cardiothoracic Surgery Cottingham, East Yorkshire United Kingdom HU16 5JQ

Sponsor information

Organisation Department of Health (UK)

Sponsor details Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type Government

Website http://www.doh.gov.uk

Funder(s)

Funder type Government

Funder Name The North and South Bank Research and Development Consortium (UK)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2005		Yes	No